

1 **Investigating pleiotropy between depression and autoimmune diseases using the UK Biobank.**

2 Kylie P Glanville¹, Jonathan R I Coleman^{1,2}, Paul F O'Reilly³, *James Galloway⁴, *Cathryn M
3 Lewis^{1,2,5}

4 *Contributed equally and share senior authorship.

5 1. Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &
6 Neuroscience, King's College London, London, GB

7 2. NIHR Biomedical Research Centre, South London and Maudsley NHS Trust, King's College
8 London, London, GB

9 3. Genetics and Genomic Sciences, Icahn School of Medicine, Mount Sinai, New York, NY, US

10 4. Department of Inflammation Biology, King's College London, London, GB

11 5. Department of Medical & Molecular Genetics, King's College London, London, GB

12

13 **Address correspondence to** Kylie P. Glanville, kylie.glanville@kcl.ac.uk; Social, Genetic and
14 Developmental Psychiatry Centre; Institute of Psychiatry, Psychology & Neuroscience; King's
15 College London, de Crespigny Park, London SE5 8AF; UK.

16 Abstract

17 **Background:** Epidemiological studies have shown increased comorbidity between depression
18 and autoimmune diseases. The mechanisms driving the comorbidity are poorly understood, and
19 a highly powered investigation is needed to understand the relative importance of shared genetic
20 influences. We investigated the evidence for pleiotropy from shared genetic risk alleles between
21 these traits in the UK Biobank (UKB).

22 **Methods:** We defined autoimmune and depression cases using information from hospital
23 episode statistics, self-reported conditions and medications, and mental health questionnaires.
24 Pairwise comparisons of depression prevalence between autoimmune cases and controls, and
25 vice-versa, were performed. Cross-trait polygenic risk score (PRS) analyses were performed to
26 test for pleiotropy, i.e. testing whether PRS for depression could predict autoimmune disease
27 status, and vice-versa.

28 **Results:** We identified 28k cases of autoimmune diseases (pooling across 14 traits) and 324k
29 autoimmune controls, and 65k cases of depression and 232k depression controls. The prevalence
30 of depression was significantly higher in autoimmune cases compared to controls, and vice-versa.
31 PRS for myasthenia gravis and psoriasis were significantly higher in depression cases compared
32 to controls ($p < 5.2 \times 10^{-5}$, $R^2 \leq 0.04\%$). PRS for depression were significantly higher in
33 inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis and type 1
34 diabetes cases compared to controls ($p < 5.8 \times 10^{-5}$, R^2 range 0.06% to 0.27%), and lower in coeliac
35 disease cases compared to controls ($p < 5.4 \times 10^{-7}$, R^2 range 0.11% to 0.15%).

36 **Conclusions:** Consistent with the literature, depression was more common in individuals with
37 autoimmune diseases compared to controls, and vice-versa, in the UKB. PRS showed some
38 evidence for involvement of shared genetic factors, but the modest R^2 values suggest that shared
39 genetic architecture accounts for only a small proportion of the increased risk across traits.

40 Introduction

41 There is evidence that individuals with a history of autoimmune disease are at greater risk for
42 developing depression¹⁻⁴, and that a history of depression increases risk for developing
43 autoimmune diseases^{5,6}. The mechanisms driving the bi-directional relationship are poorly
44 understood, but one contributory factor may be that these diseases share biological pathways.
45 We and others have shown that there is no strong evidence for the involvement of Human
46 Leukocyte Antigen (HLA) alleles in risk for depression, suggesting that the Major
47 Histocompatibility Complex (MHC) does not harbor shared risk for depression and autoimmune
48 diseases⁶⁻⁸. However, genetic risk for autoimmune diseases occurs across the genome⁹, and
49 pleiotropic effects outside the MHC may be involved in shared risk for depression and
50 autoimmune diseases.

51 Few studies have investigated evidence for genome-wide pleiotropy between depression and
52 autoimmune diseases. Euesden, et al.¹⁰ found no evidence for association between polygenic risk
53 scores (PRS) for depression and risk for rheumatoid arthritis, or vice-versa. The Psychiatric
54 Genomics Consortium (PGC) indicated no evidence for significant genetic correlations (rG)
55 between depression and nine autoimmune diseases (after multiple testing correction across 221
56 traits in total); the strongest correlation observed was between depression and inflammatory
57 bowel disease (rG = .07, uncorrected p = .01)¹¹. Recently, Liu, et al.⁶ found no association
58 between PRS for mental health disorders and risk for autoimmune diseases, and only a weak
59 association between PRS for autoimmune diseases and risk for mental health disorders.

60 We extend previous work, leveraging the UK Biobank (UKB) to test for pleiotropy between
61 depression and autoimmune diseases with PRS methodology. Given the challenge of reliably
62 defining complex disease traits using large-scale data, we take two approaches to defining
63 autoimmune diseases and depression. We classified liberally-defined cases, based on a single
64 item endorsing diagnosis with an autoimmune disease, and strictly-defined cases, based on
65 multiple items. We use this approach to identify individuals affected by any of fourteen
66 autoimmune or autoinflammatory traits - collectively referred to as autoimmune diseases
67 throughout. We take a similar approach to classifying depression by requiring a greater number
68 of endorsements in strictly-defined cases than liberally-defined cases. Liberally-defined cases
69 increase the sample size, while strictly-defined cases will reduce the rate of misclassification. We
70 perform cross-trait PRS analyses, testing for association between PRS for autoimmune diseases
71 and depression, and vice-versa. Motivated by the observation of sex-dependent genetic
72 correlations between schizophrenia and autoimmune diseases¹², and by higher prevalence in
73 females of both depression and autoimmune diseases, we stratified PRS analyses by sex. Our
74 study is one of the largest to explore pleiotropy between depression and autoimmune diseases
75 and elucidates the contribution of shared genetic influences to the observed comorbidity.

76 Methods

77 Participants

78 The UKB is a prospective health study of 500,000 individuals in the United Kingdom. Participants
79 were identified through NHS patient registers if they were aged 40-69 during the recruitment
80 phase (2006-2010) and living in proximity to an assessment centre. Participants attended a
81 baseline assessment and contributed health information via touchscreen questionnaires and
82 verbal interviews¹³. Subsets of participants completed repeat assessments: instance 1) n = 20,335
83 between 2012-2013; instance 2) n = 42,961 (interview) and n = 48,340 (touchscreen) in 2014;
84 and instance 3) n = 2,843 (interview) and n = 3,081 (touchscreen) in 2019. Participant data are
85 linked to Hospital Episode Statistics (HES) containing information on episodes of inpatient care.
86 Episodes are coded at admission using the International Classification of Diseases, 10th Revision¹⁴
87 (ICD-10). Inpatients are assigned one primary code (reason for admission) and a variable number
88 of secondary codes. Additional data are available for psychiatric phenotyping, including an online
89 Mental Health Questionnaire (MHQ) completed by 157,366 participants in 2017¹⁵. The UKB
90 received ethical approval from the North West - Haydock Research Ethics Committee (reference
91 16/NW/0274). Participants provided electronic signed consent at recruitment¹³.


92 Autoimmune phenotyping

93 Guided by studies that investigated the epidemiological relationship between autoimmune
94 diseases and depression^{1,5}, we identified cases for fourteen autoimmune diseases: pernicious

95 anemia (PA), autoimmune thyroid disease (ATD), type 1 diabetes (T1D), multiple sclerosis (MS),
96 myasthenia gravis (MG), coeliac, inflammatory bowel disease (IBD; includes crohn's disease and
97 ulcerative colitis), psoriasis, ankylosing spondylitis (AS), polymyalgia rheumatica/giant cell
98 arteritis (PR/GCA), psoriatic arthritis (PsA), rheumatoid arthritis (RA), sjögren syndrome (SS), and
99 systemic lupus erythematosus (SLE).

100 Two sources of information were used to define autoimmune cases and controls. (1) HES: primary
101 and secondary ICD-10 diagnoses recorded between April 1997 to October 2016 were identified
102 from the UKB Data Portal Record Repository. (2) Verbal interview: participants' responses at
103 baseline or instance 1 or 2 to determine self-endorsed medical conditions (past and current) and
104 self-endorsed prescription medications (current). ICD-10 codes, self-endorsed conditions and
105 medications used to define each autoimmune disease are listed in the Supplementary Material.

106 We took two approaches to defining autoimmune cases (Figure 1). To increase sample size, we
107 created 'possible' cases, comprising participants with an ICD-10 diagnosis or a self-endorsed
108 condition. To increase validity, we used multiple observations to create 'probable' cases.
109 Participants were coded as probable cases if at least two of ICD-10 diagnosis, self-endorsed
110 condition or medication were observed. More than one ICD-10 diagnosis for the corresponding
111 autoimmune disease was also sufficient. A set of autoimmune controls was defined from
112 participants with no ICD-10 diagnoses, self-endorsed conditions or medications for all fourteen
113 autoimmune diseases. A single set of controls was used for all autoimmune diseases, given the
114 known comorbidity between them.



115

116 Figure 1: Autoimmune phenotyping approach. Cases are included in possible or probable if they fall within a
117 shaded area. Autoimmune medication was used as a confirmatory, but not a primary source of information,
118 because several medications are not disease-specific.

119

120 Depression phenotyping

121 We created two depression case groups: strictly-defined cases termed 'stringent depression' and
122 liberally-defined cases termed 'any depression'. We have previously shown that SNP-based
123 heritability increases with multiple endorsements of depression¹⁶. We therefore classified
124 'stringent depression' as participants endorsing at least three of the following depression
125 measures: ICD-10 diagnoses (F32-F33.9); self-reported depression; self-reported antidepressant
126 usage; single or recurrent depression (defined by Smith, et al.¹⁷ from responses to a
127 questionnaire completed at baseline by 172,751 participants); or answered 'yes' to the

128 questionnaire: "Have you ever seen a GP/psychiatrist for nerves, anxiety, tension or
129 depression?".

130 We classified 'any depression' as participants who endorsed two or more depression measures,
131 or if they met criteria for lifetime depression in the Composite International Diagnostic Interview
132 (CIDI) assessed in the MHQ¹⁵. We classify cases defined from CIDI alone as 'any depression' not
133 as 'stringent depression' because we previously observed lower SNP-based heritability in this
134 group ($h^2_{\text{SNP}} = 11\%$, $SE = 0.008$) compared to cases defined by three or more non-CIDI measures
135 of depression ($h^2_{\text{SNP}} = 19\%$, $SE = 0.018$)¹⁶.

136 Depression cases were screened for schizophrenia and bipolar according to any indication: ICD-
137 10 diagnoses (F20-29, F30-31.9, F34-39); self-endorsed conditions (schizophrenia, mania, bipolar
138 disorder or manic depression) or self-endorsed antipsychotic usage reported at baseline or
139 instance 1 or 2; Bipolar Type I (Mania) or Bipolar Type II (Hypomania) according to the criteria
140 adopted by Smith, et al.¹⁷; or indications of psychosis endorsed in the MHQ. A single set of
141 depression controls was defined from participants who did not meet the criteria for depression,
142 schizophrenia or bipolar.

143 Derivation of depression, schizophrenia and bipolar indications can be found in Supplementary
144 Materials from our previous publication¹⁶.

145 Genetic quality control (QC)

146 The UKB performed preliminary QC on genotype data assayed for all participants¹³. Using genetic
147 principal components (PCs) provided by the UKB, we performed 4-means clustering on the first
148 two PCs to identify and retain individuals of European ancestry. QC was then performed using
149 PLINK v1.9¹⁸ to remove: variants with missingness > 0.02 (before individual QC), individuals with
150 missingness > 0.02, individuals whose self-reported sex was discordant from their genetic sex,
151 variants with missingness > 0.02 (after individual QC), variants departing from Hardy-Weinberg
152 Equilibrium ($p < 10e-8$), and variants with minor allele frequency (MAF) < 0.01. Relatedness
153 kinship estimates provided by the UKB were used to identify pairs of related individuals (KING r^2
154 > 0.044)¹⁹ and the GreedyRelated²⁰ algorithm used to remove one individual from each pair,
155 preferentially retaining individuals that survived QC. FlashPCA2²¹ was used to generate PCs for
156 the sub-set of individuals of European ancestry surviving QC. PRS analyses were performed using
157 genotype data.

158 Statistical analyses

159 We summarised sociodemographic data taken at baseline assessment: age, sex, socio-economic
160 status (SES), body mass index (BMI) and current smoking status. We tested for significant
161 differences in sociodemographic variables between cases and controls using Welch Two Sample
162 t-tests in R v3.6²². We tested for significant differences in: 1) the prevalence of depression in
163 autoimmune cases compared to autoimmune controls, and 2) the prevalence of autoimmune
164 diseases in depression cases compared to depression controls. These tests were performed for

165 both probable/possible autoimmune cases and stringent/any depression, using 2-sample tests
166 for equality of proportions in R v3.6²².

167 [Summary statistics for autoimmune diseases and depression](#)

168 We searched PubMed and the NHGRI-EBI GWAS Catalog
169 (<https://www.ebi.ac.uk/gwas/downloads/summary-statistics>) for the latest genome-wide
170 association study (GWAS) with publicly-available summary statistics, using the name of the
171 relevant trait (and “GWAS” or “genome-wide association study” on PubMed). We identified
172 summary statistics for eight of the fourteen autoimmune diseases: coeliac²³, IBD²⁴, MS²⁵, MG²⁶,
173 psoriasis²⁷, PsA²⁸, RA²⁹, and SLE³⁰ (Table 1). For MG, psoriasis and PsA, we contacted the authors
174 of the primary GWASs directly to obtain access. Summary statistics from GWAS using the
175 ImmunoChip were excluded as it does not provide genome-wide coverage. For Major Depressive
176 Disorder (MDD), we used summary statistics from Wray, et al.¹¹, excluding UKB.

177 Table 1: GWAS summary statistics used to generate polygenic risk scores.

Trait	Year	Ancestry	Assembly	Cases	Controls
Coeliac Disease	2010	European	GRCh37/hg19	4,533	10,750
Inflammatory Bowel Disease	2015	European	GRCh37/hg19	12,882	21,770
Multiple Sclerosis	2011	European	GRCh37/hg19	9,772	17,376
Myasthenia Gravis	2015	European	GRCh37/hg19	1,032	1,998
Psoriasis	2017	European	GRCh37/hg19	19,032	286,769
Psoriatic Arthritis	2018	European	GRCh37/hg19	1,430	1,417
Rheumatoid Arthritis	2014	European	GRCh37/hg19	14,361	43,923
System Lupus Erythematosus	2015	European	GRCh37/hg19	7,219	15,991
Major Depressive Disorder	2018	European	GRCh37/hg19	116,404	314,990

178

179 Polygenic risk score (PRS) analyses

180 PRS analyses were conducted using the PRSice-2 software³¹. QC was performed on summary
181 statistics to remove variants within the MHC (28.8 to 33.7 Mb), and default clumping settings
182 were applied in PRSice-2 to remove variants in linkage disequilibrium ($r^2 > 0.1$) with the lead
183 variant within a 250kb region.

184 To validate our phenotyping approach, we tested for association between PRS for eight
185 autoimmune diseases and case-control status for the corresponding diseases (possible and
186 probable cases), and between PRS for MDD and case-control status for depression (any and
187 stringent).

188 To investigate pleiotropy between autoimmune diseases and depression we performed cross-
189 trait analyses, testing for association between 1) PRS for eight autoimmune diseases and case-
190 control status for depression (any and stringent cases); and 2) PRS for MDD and case-control
191 status for fourteen autoimmune diseases (possible and probable cases). To test for sex-specific
192 effects, we performed cross-trait analyses in males and females separately.

193 For each test, PRS constructed at eight p-value thresholds (P_T ; 0.001, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5
194 and 1.0) were regressed on case-control status using logistic regression, adjusting for the
195 following covariates: six PCs, genotyping batch, and assessment centre ($n=128$ variables). We
196 report p-values at the optimal P_T for each test of association. To control for multiple testing across
197 P_T (x8), and across tests of association (autoimmune PRS (x8) predicting any/stringent depression
198 (x2) in men and women (x2), $n=32$; and MDD PRS predicting possible/probable (x2) autoimmune

199 diseases (x14) in men and women (x2), n=56), a Bonferroni correction was applied to give a p-
200 value threshold for significance of 7.1×10^{-5} ($0.05/704$ tests, $704 = 8 \times (32+56)$). Where sex-specific
201 associations were observed, sensitivity analyses were conducted to account for different sample
202 sizes between sexes. We tested for interactions between sex and PRS (at the optimal P_T from sex-
203 specific tests) in the full sample (Phenotype \sim sex + PRS + sex*PRS + covariates). We report R^2
204 estimates transformed to the liability scale using the following population prevalences for
205 outcome traits: PA=0.1%³², ATD=2%³³, T1D=0.3%³⁴, MS=0.1%²⁵, MG=0.02%³⁵, coeliac=1%²³,
206 IBD=0.5%²⁴, psoriasis=2%³⁶, AS=0.55%³⁷, PR/GCA= 0.85%³⁸, PsA=0.5%²⁸, RA=1%³⁹, SS=0.7%⁴⁰,
207 SLE=0.1%⁴¹ and MDD=15%¹¹.

208 AVENGEME⁴² was used to estimate power to detect cross-trait PRS associations, assuming
209 varying degrees of genetic correlation (r_G) between corresponding traits (r_G 0.01 to 0.5). Power
210 was estimated for cross-trait analyses where summary statistics for both traits were available
211 (i.e. eight autoimmune disorders and MDD) so that SNP-based heritability (required for power
212 calculations in AVENGEME) could be estimated using Linkage Disequilibrium Score Regression
213 (LDSC v1.0.1)⁴³ (Supplementary Figure 1). Power was estimated using PRS at the optimal P_T
214 identified in cross-trait association tests, and liberally-defined sample sizes. Parameters used to
215 estimate power are in Supplementary Tables 1 and 2.

216 LDSC v1.0.1⁴³ was used to estimate r_G between the UKB depression phenotypes ('any' and
217 'stringent') and autoimmune diseases with publicly-available summary statistics. To robustly
218 apply LDSC, we limited the autoimmune diseases to those with sample sizes above 5k in the

219 primary GWAS (coeliac²³, IBD²⁴, MS²⁵, psoriasis²⁷, RA²⁹, and SLE³⁰). To control for multiple testing
220 across traits, a Bonferroni correction was applied to give a p-value threshold for significance of
221 4.1×10^{-3} in rG analyses (0.05/12 tests).

222 Results

223 A total of 28,479 individuals were identified as possible cases across fourteen autoimmune
224 diseases, and a sub-set of 16,824 (59.1%) met the stringent criteria for probable cases (refer
225 Supplementary Material for representation of the overlap between criteria used to define cases).
226 65,075 individuals met the criteria for any depression, 14,625 of whom met the criteria for
227 stringent depression. Sociodemographic characteristics for autoimmune and depression cases
228 and controls are summarised in Table 2. Overall, autoimmune and depression case groups
229 contained a higher proportion of females, had lower SES, higher smoking prevalence, and higher
230 BMI than their respective control groups, (N = 324,074 autoimmune controls, N = 232,552
231 depression controls, all p-values < 5×10^{-21} in pairwise comparisons).

232 Table 2: Sociodemographic information for autoimmune and depression cases and controls. Pop. Prev. = population prevalence estimate. UKB Prev. = prevalence of cases
 233 in the UKB as a proportion of autoimmune/depression controls. TDI = Townsend Deprivation Index; negative scores indicate less deprivation. SD = standard deviation.

		Pop. Prev.	Count	UKB Prev.	Mean age (SD)	Female (%)	TDI (SD)	Current smoker (%)	Mean BMI (SD)	Count	UKB Prev.	Mean age (SD)	Female (%)	TDI (SD)	Current smoker (%)	Mean BMI (SD)
Autoimmune Diseases (system/disease)			Possible						Probable							
Blood	Pernicious Anemia	0.10%	1,555	0.48%	58.9 (7.61)	71%	-0.85 (3.19)	13%	28.0 (5.55)	423	0.13%	60.1 (7.19)	72%	-0.99 (3.23)	12%	28.5 (5.34)
Endocrine system	Autoimmune Thyroid Disease	2.00%	859	0.26%	56.8 (7.75)	85%	-1.11 (3.05)	15%	27.4 (5.11)	607	0.19%	57.0 (7.64)	86%	-1.06 (3.03)	16%	27.8 (5.21)
	Type 1 diabetes	0.30%	2,751	0.84%	58.3 (7.80)	42%	-0.46 (3.39)	13%	30.1 (6.08)	2,292	0.70%	58.0 (7.85)	43%	-0.50 (3.39)	12%	29.9 (6.07)
Nervous system	Multiple Sclerosis	0.10%	1,683	0.52%	55.4 (7.52)	73%	-1.45 (3.01)	16%	26.9 (5.08)	1,154	0.35%	55.5 (7.45)	73%	-1.33 (3.06)	17%	26.9 (5.27)
	Myasthenia Gravis	0.02%	234	0.07%	59.2 (7.39)	56%	-0.94 (3.27)	11%	29.0 (5.44)	147	0.05%	60.1 (7.09)	48%	-1.06 (3.32)	12%	29.3 (5.18)
Digestive system	Coeliac	1.00%	2,364	0.72%	57.8 (7.79)	67%	-1.49 (2.99)	7%	25.8 (4.57)	1,260	0.39%	58.4 (7.66)	68%	-1.42 (3.03)	7%	25.8 (4.60)
	Inflammatory Bowel Disease	0.50%	5,105	1.55%	57.4 (7.92)	51%	-1.27 (3.10)	10%	27.3 (4.70)	3,538	1.08%	57.3 (7.98)	50%	-1.28 (3.07)	9%	27.2 (4.63)
Skin	Psoriasis	2.00%	5,459	1.66%	56.8 (8.01)	46%	-1.05 (3.22)	15%	28.4 (5.17)	2,759	0.84%	57.1 (8.04)	42%	-0.90 (3.28)	16%	28.7 (5.26)
Musculoskeletal system and connective tissue	Ankylosing Spondylitis	0.55%	1,344	0.41%	57.9 (7.47)	38%	-1.02 (3.21)	13%	27.8 (4.80)	413	0.13%	57.4 (7.57)	26%	-1.06 (3.22)	12%	27.9 (4.85)
	Polymyalgia Rheumatica/GCA	0.85%	1,627	0.50%	63.1 (5.16)	67%	-1.70 (2.79)	9%	28.3 (5.08)	898	0.28%	63.7 (4.58)	68%	-1.67 (2.75)	9%	28.4 (5.24)
	Psoriatic Arthritis	0.50%	1,107	0.34%	56.6 (7.48)	50%	-1.16 (3.18)	11%	29.0 (5.43)	779	0.24%	56.6 (7.52)	51%	-1.06 (3.23)	11%	29.3 (5.59)
	Rheumatoid Arthritis	1.00%	6,360	1.92%	59.5 (7.06)	67%	-0.91 (3.29)	13%	28.5 (5.53)	3,451	1.05%	59.6 (7.01)	70%	-1.08 (3.18)	12%	28.2 (5.50)
	Sjögren Syndrome	0.70%	647	0.20%	59.3 (7.10)	90%	-1.20 (3.03)	6%	27.1 (5.72)	389	0.12%	59.2 (7.26)	89%	-1.19 (3.10)	7%	27.0 (5.55)
	Systemic Lupus Erythematosus	0.10%	624	0.19%	56.7 (8.18)	84%	-1.02 (3.21)	14%	27.3 (5.65)	362	0.11%	56.6 (8.00)	86%	-0.99 (3.15)	14%	27.3 (5.82)
Any Autoimmune Disease		NA	28,479	8.08%	58.1 (7.73)	58%	-1.11 (3.17)	12%	27.9 (5.28)	16,824	4.94%	58.1 (7.73)	57%	-1.10 (3.17)	12%	28.0 (5.34)
<i>Autoimmune Controls</i>		NA	324,074	NA	56.4 (8.06)	52%	-1.50 (2.98)	10%	27.2 (4.64)	324,074	NA	56.4 (8.06)	52%	-1.50 (2.98)	10%	27.2 (4.64)
Depression			Any						Stringent							
Depression		15%	65,075	21.86%	55.4 (7.86)	67%	-1.09 (3.14)	13%	27.8 (5.32)	14,625	5.92%	56.1 (7.88)	67%	-0.58 (3.35)	19%	28.9 (5.77)
<i>Depression Controls</i>		NA	232,552	NA	57.1 (8.10)	47%	-1.65 (2.89)	9%	27.2 (4.53)	232,552	NA	57.1 (8.10)	47%	-1.65 (2.89)	9%	27.2 (4.53)

234

235 The prevalence of any depression was significantly higher in autoimmune cases compared to
 236 autoimmune controls ($p = 6 \times 10^{-177}$ for possible cases of any autoimmune disease versus controls, $p =$
 237 2×10^{-124} for probable cases of any autoimmune disease versus controls). The prevalence of stringent
 238 depression was significantly higher in autoimmune cases compared to autoimmune controls ($p = 3 \times 10^{-$
 239 207 for possible cases of any autoimmune disease versus controls, $p = 6 \times 10^{-163}$ for probable cases of any
 240 autoimmune disease versus controls) (Table 3).

241 Table 3: Prevalence of depression within autoimmune cases compared to autoimmune controls, stratified by
 242 possible/probable for autoimmune diseases, and any/stringent for depression cases. P-values from pairwise
 243 comparisons of depression prevalence in autoimmune cases compared to autoimmune controls are shown in brackets.

Autoimmune Trait		Depression prevalence in autoimmune traits			
		Any depression prevalence		Stringent depression prevalence	
		Possible Autoimmune	Probable Autoimmune	Possible Autoimmune	Probable Autoimmune
Autoimmune Controls		20.6%		5.1%	
Any Autoimmune Disease		28.9% (6×10^{-177})	29.5% (2×10^{-124})	10.8% (3×10^{-207})	11.5% (6×10^{-163})
Blood	Pernicious Anemia	35.8% (4×10^{-36})	33.7% (4×10^{-8})	15.2% (1×10^{-39})	16.6% (4×10^{-15})
Endocrine system	Autoimmune Thyroid Disease	35.1% (6×10^{-19})	34.7% (6×10^{-13})	13.7% (1×10^{-16})	13.4% (3×10^{-11})
	Type 1 diabetes	31.1% (3×10^{-31})	31.3% (1×10^{-27})	14.1% (5×10^{-59})	13.5% (5×10^{-43})
Nervous System	Multiple Sclerosis	39.3% (6×10^{-56})	42.5% (3×10^{-51})	16.9% (5×10^{-54})	20.0% (8×10^{-57})
	Myasthenia Gravis	33.3% (5×10^{-5})	29.2% (3×10^{-2})	14.1% (5×10^{-6})	14.8% (4×10^{-5})
Digestive system	Coeliac	27.3% (3×10^{-12})	29.8% (2×10^{-12})	8.4% (4×10^{-8})	9.5% (7×10^{-8})
	Inflammatory Bowel Disease	24.9% (6×10^{-11})	24.9% (3×10^{-8})	8.9% (8×10^{-22})	9.1% (2×10^{-17})
Skin	Psoriasis	26.8% (2×10^{-22})	28.3% (1×10^{-17})	8.7% (4×10^{-20})	9.9% (4×10^{-18})
Musculoskeletal system and connective tissue	Ankylosing Spondylitis	26.9% (5×10^{-7})	28.4% (5×10^{-4})	9.6% (7×10^{-9})	10.5% (9×10^{-5})
	Polymyalgia Rheumatica/GCA	29.3% (2×10^{-13})	27.8% (5×10^{-6})	10.8% (3×10^{-15})	10.6% (1×10^{-8})
	Psoriatic Arthritis	31.8% (3×10^{-15})	34.3% (5×10^{-16})	10.2% (1×10^{-8})	13.0% (2×10^{-13})
	Rheumatoid Arthritis	30.6% (5×10^{-62})	29.4% (6×10^{-28})	12.7% (3×10^{-92})	12.1% (1×10^{-45})
	Sjögren Syndrome	40.7% (4×10^{-25})	41.9% (1×10^{-17})	18.9% (2×10^{-28})	18.9% (7×10^{-18})
	Systemic Lupus Erythematosus	40.2% (2×10^{-25})	44.5% (2×10^{-22})	18.8% (6×10^{-30})	22.2% (8×10^{-27})


244 The prevalence of possible cases of any autoimmune disease was significantly higher in depression cases
 245 compared to depression controls ($p = 6 \times 10^{-177}$ for any depression versus controls, $p = 3 \times 10^{-207}$ for
 246 stringent depression versus controls). The prevalence of probable cases of any autoimmune disease was
 247 significantly higher in depression cases compared to depression controls ($p = 2 \times 10^{-124}$ for any depression
 248 versus controls, $p = 6 \times 10^{-163}$ for stringent depression versus controls) (Table 4).

249 Table 4: Prevalence of autoimmune diseases within depression cases compared to depression controls, stratified by
 250 possible/probable for autoimmune diseases, and stringent/any for depression cases. P-values from pairwise
 251 comparisons of autoimmune prevalence in depression cases compared to depression controls are shown in brackets.

		Autoimmune prevalence in depression					
		Possible autoimmune prevalence			Probable autoimmune prevalence		
Autoimmune Trait		Any Depression	Stringent Depression	Depression Controls	Any Depression	Stringent Depression	Depression Controls
Any Autoimmune Disease		10.48% (6×10^{-177})	14.27% (3×10^{-207})	6.94%	6.59% (2×10^{-124})	9.48% (6×10^{-163})	4.19%
Blood	Pernicious Anemia	0.77% (4×10^{-36})	1.17% (1×10^{-39})	0.36%	0.19% (4×10^{-8})	0.35% (4×10^{-15})	0.10%
Endocrine system	Autoimmune Thyroid Disease	0.41% (6×10^{-19})	0.58% (1×10^{-16})	0.20%	0.28% (6×10^{-13})	0.39% (3×10^{-11})	0.14%
	Type 1 diabetes	1.20% (3×10^{-31})	2.07% (5×10^{-59})	0.69%	1.02% (1×10^{-27})	1.65% (5×10^{-43})	0.58%
Nervous System	Multiple Sclerosis	0.87% (6×10^{-56})	1.31% (5×10^{-54})	0.35%	0.63% (3×10^{-51})	1.02% (8×10^{-57})	0.22%
	Myasthenia Gravis	0.11% (5×10^{-5})	0.17% (5×10^{-6})	0.05%	0.06% (3×10^{-2})	0.12% (4×10^{-5})	0.04%
Digestive system	Coeliac	0.92% (3×10^{-12})	1.08% (4×10^{-8})	0.64%	0.54% (2×10^{-12})	0.64% (7×10^{-8})	0.33%
	Inflammatory Bowel Disease	1.82% (6×10^{-11})	2.56% (8×10^{-22})	1.43%	1.28% (3×10^{-8})	1.85% (2×10^{-17})	1.00%
Skin	Psoriasis	2.05% (2×10^{-22})	2.55% (4×10^{-20})	1.46%	1.10% (1×10^{-17})	1.47% (4×10^{-18})	0.73%
Musculoskeletal system and connective tissue	Ankylosing Spondylitis	0.52% (5×10^{-7})	0.72% (7×10^{-9})	0.37%	0.17% (5×10^{-4})	0.25% (9×10^{-5})	0.11%
	Polymyalgia Rheumatica/GCA	0.66% (2×10^{-13})	0.93% (3×10^{-15})	0.42%	0.35% (5×10^{-6})	0.51% (1×10^{-8})	0.23%
	Psoriatic Arthritis	0.50% (3×10^{-15})	0.58% (1×10^{-8})	0.28%	0.38% (5×10^{-16})	0.51% (2×10^{-13})	0.19%
	Rheumatoid Arthritis	2.66% (5×10^{-62})	4.14% (3×10^{-92})	1.59%	1.42% (6×10^{-28})	2.23% (1×10^{-45})	0.89%
	Sjögren Syndrome	0.34% (4×10^{-25})	0.55% (2×10^{-28})	0.13%	0.21% (1×10^{-17})	0.33% (7×10^{-18})	0.08%
	Systemic Lupus Erythematosus	0.36% (2×10^{-25})	0.59% (6×10^{-30})	0.14%	0.23% (2×10^{-22})	0.39% (8×10^{-27})	0.08%

252

253 Testing for same-trait PRS associations, PRS for MDD were significantly associated with any depression
 254 case-status ($p < 5 \times 10^{-324}$, $R^2 = 1.48\%$) and stringent depression case-status ($p = 2 \times 10^{-228}$, $R^2 = 2.23\%$). PRS
 255 for autoimmune diseases were significantly associated with both possible and probable case-control
 256 status for the corresponding diseases (Figure 2). The variance in liability, R^2 , explained by PRS was higher
 257 in strictly-defined compared to liberally-defined phenotypes. Most results were highly significant ($p <$
 258 6×10^{-29}), except myasthenia gravis ($p < 7 \times 10^{-3}$), which has the smallest sample size of 234 cases, and
 259 psoriatic arthritis ($p < 3 \times 10^{-6}$) where the discovery GWAS has only 1430 cases.



260


261 Figure 2: Variances in autoimmune liability explained by PRS for the corresponding autoimmune diseases. The number
 262 of cases are shown at the top of the plot (possible = blue, probable = red). P-values are shown atop each bar.

263

264 Power analyses showed that, in the prediction of any depression from autoimmune PRS, there was 80%
 265 power to detect associations assuming modest levels of underlying genetic correlation (r_G); $r_G < 0.05$ for
 266 coeliac, MS, psoriasis, and SLE; $r_G < 0.1$ for IBD, PsA and RA; and $r_G < 0.17$ for MG (Supplementary Figure

267 2). In the prediction of possible autoimmune diseases from depression PRS, there was 80% power to
 268 detect associations assuming $r_G < 0.05$ for coeliac and IBD; $r_G < 0.1$ for psoriasis and RA; and $r_G < 0.15$
 269 for PsA and SLE. There were two exceptions; MS and MG, where the underlying r_G would need to
 270 approach ~ 0.3 to achieve 80% power (Supplementary Figure 3).

271 In the prediction of depression from autoimmune PRS (Figure 3), PRS for myasthenia gravis were
 272 significantly associated with case-status for any depression ($p = 5.2 \times 10^{-5}$, $R^2 = 0.01\%$) and stringent
 273 depression ($p = 1.6 \times 10^{-5}$, $R^2 = 0.04\%$). PRS for psoriasis were significantly associated with case-status for
 274 any depression ($p = 8.7 \times 10^{-6}$, $R^2 = 0.01\%$). No other autoimmune disease PRS predicted depression case-
 275 control status, and no sex-specific analyses met the Bonferroni-corrected threshold. The R^2 values for
 276 variance explained in depression by autoimmune PRS are all very low, at $< 0.1\%$, and substantially lower
 277 than the R^2 for autoimmune diseases (Figure 2).



278


279 Figure 3: Variances in depression liability explained by PRS for autoimmune diseases (x-axis). Asterisks denote
 280 associations with p -values $< 7.1 \times 10^{-5}$, meeting Bonferroni correction. Number of cases for depression phenotypes: Any
 281 (combined) = 65,075; Any (female) = 43,413; Any (male) = 21,662; Stringent (combined) = 14,625; Stringent (female) =
 282 9,738; Stringent (male) = 4,887.

283

284 In the prediction of autoimmune diseases from depression PRS, genetic liability for MDD was
285 significantly associated with six autoimmune diseases: coeliac, inflammatory bowel disease, psoriasis,
286 psoriatic arthritis, rheumatoid arthritis, and type 1 diabetes (all p-values < 5.8×10^{-5} , R^2 range between
287 0.06% and 0.27%) (Figure 4). For three, the association with MDD was observed in probable and possible
288 cases (psoriasis, rheumatoid arthritis and type 1 diabetes). For coeliac and inflammatory bowel disease,
289 the association was only in possible cases. For psoriatic arthritis, the association was only in probable
290 cases. For all significant associations, higher PRS increased risk for the outcome phenotype, except for
291 coeliac, where higher MDD PRS was associated with reduced risk ($p = 6 \times 10^{-8}$, $R^2 = 0.17\%$, $\beta = -0.11$, SE
292 = 0.02, in the combined sample).

293 In the prediction of autoimmune diseases from depression PRS, sex-specific associations were observed,
294 primarily in female autoimmune cases (coeliac, inflammatory bowel disease, type 1 diabetes and
295 rheumatoid arthritis, all $p < 4.5 \times 10^{-5}$). Association in males was observed in psoriasis (possible cases, $p =$
296 5.8×10^{-5}), and in rheumatoid arthritis (possible cases, $p = 1.6 \times 10^{-5}$). The most consistent results were
297 observed in rheumatoid arthritis, where the sample size was largest, with five of the six analyses reaching
298 Bonferroni threshold (all $p < 4.5 \times 10^{-5}$, R^2 range between 0.07% and 0.1%). However, there was no
299 evidence for a significant interaction between sex and PRS in the combined samples of men and women
300 (all $p > 0.02$), indicating that sex-specific associations were generally influenced by sample size.

301 Full results of each test are shown in Supplementary Tables 3 to 6 and Supplementary Figures 4 to 7.



302

303 Figure 4: Variances in autoimmune liability (x-axes) explained by PRS for MDD. Asterisks denote associations with p-
 304 values < 7.1x10⁻⁵, meeting Bonferroni correction. Number of cases for the autoimmune diseases are given in Table 2.

305

306 Significant genetic correlations (rG) were observed between inflammatory bowel disease and any
 307 depression (rG = 0.11, 95% CI = 0.03 - 0.18, p = 3.8x10⁻³) and stringent depression (rG = 0.16, 95% CI =
 308 0.07 - 0.24, p = 3.0x10⁻⁴); and between psoriasis and stringent depression (rG = 0.16, 95% CI = 0.06 - 0.26,

309 $p = 1.1 \times 10^{-3}$). No other traits met the Bonferroni-corrected threshold for significance in rG analyses
310 (Supplementary Table 7).

311 Discussion

312 Motivated by epidemiological findings of a bi-directional relationship between depression and
313 autoimmune diseases, we tested for evidence of pleiotropy between traits, adopting both liberal and
314 strict phenotyping to define cases in the UKB. We showed modest association of PRS from autoimmune
315 diseases with MDD, and slightly stronger associations of MDD PRS with autoimmune diseases. These
316 observations suggest only a minor component of observed comorbidity is due to shared genetics
317 between depression and autoimmune diseases.

318 We made three key observations: 1) Phenotypic variance explained by PRS for corresponding traits was
319 higher in strictly-defined than liberally-defined cases, indicating more rigorous phenotyping improved
320 the validity of autoimmune and depression cases; 2) The phenotypic overlap between depression and
321 autoimmune diseases was consistent with the literature – depression was more common in individuals
322 with autoimmune diseases, and vice-versa; 3) Cross-trait PRS analyses identified significant associations
323 between depression and some autoimmune diseases, but with effect sizes indicating the existence of a
324 shared biological component of modest effect on the observed comorbidity.

325 Our phenotyping approach used both strictly-defined and liberally-defined cases, integrating the
326 multiple sources of UKB data. PRS for eight autoimmune diseases predicted case-control status,
327 increasing confidence in the robustness of case definition. The phenotypic variance explained was higher
328 in strictly-defined cases, potentially reflecting greater specificity; identifying individuals with multiple
329 endorsements for a disease reduces the probability of misclassifying controls as cases. Conversely, the

330 criteria for liberally-defined cases increases sample size, but may induce misclassification of controls as
331 cases.

332 For each of the autoimmune diseases considered, cases had higher frequencies of depression than
333 controls, recapitulating the effect observed in epidemiological studies. Similarly, the prevalence of each
334 autoimmune disease was significantly higher in depression cases compared to controls. Prevalence
335 estimates reported here are cross-sectional, and we lack information on the temporal relationship
336 between traits.

337 Cross-trait PRS analyses identified significant associations, although observed effect sizes were small,
338 ranging between $R^2 = 0.01\%$ and 0.27% . Compared with the substantially higher phenotypic variance
339 explained by PRS for autoimmune diseases in corresponding traits, the small effect sizes observed in
340 cross-trait PRS analyses provide a useful contrast, indicating only a small contribution of shared genetic
341 influences in the observed comorbidities. However, this was not universally true – MDD PRS captured
342 nearly the same amount of variance in probable psoriatic arthritis (0.27%) as the PRS for psoriatic
343 arthritis (0.29%). For all significant associations, higher PRS increased risk for the outcome phenotype.
344 Interestingly, there was one exception, where higher MDD PRS was associated with reduced risk for
345 coeliac disease. This is intriguing given the positive phenotypic correlation between depression and
346 coeliac disease and may warrant further investigation.

347 For three traits, we observed significant associations in liberally-defined, but not strictly-defined cases
348 (psoriasis PRS was associated with any depression, MDD PRS was associated with possible coeliac and
349 inflammatory bowel disease). In contrast, MDD PRS was associated with probable, but not possible,

350 psoriatic arthritis, suggesting misclassification in possible cases. Misclassification bias may vary across
351 diseases; some autoimmune diseases may be more prone to misclassification with other autoimmune
352 diseases, whilst other diagnoses may misclassify with non-inflammatory conditions. For example,
353 osteoarthritis (non-inflammatory) may misclassify as psoriatic arthritis in the absence of multiple-item
354 endorsement to increase diagnosis validity.

355 Cross-trait PRS analyses identified some sex-dependent associations. MDD PRS were associated with
356 psoriasis in males, and MDD PRS were associated with coeliac, inflammatory bowel disease and type 1
357 diabetes in females. However, sensitivity analyses revealed no evidence for significant interactions
358 between PRS and sex in the combined sample, indicating that sex-dependent associations were generally
359 driven by different sample sizes in sex-stratified analyses. Rheumatoid arthritis was the most common
360 autoimmune disease and showed the most consistency in cross-trait associations; MDD PRS were
361 significantly associated with rheumatoid arthritis in all case groups, except probable males. This is in
362 contrast with Euesden, et al.¹⁰, found no evidence for association between PRS for depression and risk
363 for rheumatoid arthritis, but in a substantially smaller sample of 226 cases. Liu, et al.⁶ also found no
364 evidence for association between a composite mental health disorder PRS and risk for autoimmune
365 diseases, but also in a smaller sample of 1,383 individuals with any of seven autoimmune diseases. A
366 composite PRS for autoimmune diseases did show weak association with case-control status in a sample
367 of 43,902 individuals with any of six mental health disorders in the Liu, et al.⁶ study. This highlights the
368 importance of sample size, and our study benefits from the scale of the UKB, where power calculations
369 indicated our investigation was able to detect modest pleiotropic effects.

370 In contrast to the small, but significant, cross-trait PRS associations observed between depression and
371 several autoimmune diseases, we only observed significant genetic correlations between depression and
372 two autoimmune diseases: inflammatory bowel disease and psoriasis. The PRS methodology, which
373 exploits the use of individual-level data, may have increased power to detect weak genetic effects
374 compared to LDSC, which uses only summary statistics.

375 The weak genetic contribution suggests that another mechanism may be driving or contributing to the
376 bi-directional relationship between autoimmune diseases and depression⁴⁴. Inflammatory factors
377 underlying some cases of depression could provide a common biological pathogenesis with autoimmune
378 diseases. Lynall, et al.⁴⁵ observed increased immune cell counts in depression cases compared to
379 controls, and identified a sub-group of cases with elevated inflammatory markers who presented with
380 more severe depression than uninflamed cases. Environmental risk factors such as BMI and childhood
381 maltreatment increase risk of both depression and autoimmune diseases and would contribute to the
382 bi-directional effect^{46,47}. Similarly, some treatments for depression (antidepressants) and autoimmune
383 diseases (steroids) are obesogenic and may increase comorbidity. Diagnosis with autoimmune disease
384 increases risk of depression due to psychological factors in adjusting to a chronic disorder and changes
385 in behaviour such as reduced exercise. Health related behaviours that are elevated in depression
386 (smoking, poor diet and reduced physical activity) increase risk for autoimmune diseases. These
387 mechanisms may not be independent of joint genetic contributors. For example, shared inflammatory
388 mechanisms would lead to horizontal pleiotropy, where genetic variants directly affect both disorders,
389 and vertical pleiotropy can arise through environmental risk factors where genetic variation influences
390 one trait through mediation on another trait. The mechanisms underpinning the observed cross-trait

391 PRS associations may warrant further investigation, potentially using Mendelian Randomization to
392 investigate whether MDD risk alleles have a causal effect on autoimmune diseases, and vice versa. It is
393 also interesting to speculate that associations could be driven by ‘phenotypic hitchhiking’, in which a
394 GWAS for one trait (e.g. MDD) ascertains patients with comorbid diseases (e.g. autoimmune), potentially
395 inducing cross-trait correlations. Disentangling pleiotropy from ‘phenotypic hitchhiking’ may warrant
396 further investigation.

397 [Limitations](#)

398 A healthy volunteer bias has been observed in the UKB⁴⁸, and is a noted limitation of the study. However,
399 it has been proposed that this bias may attenuate, but not invalidate, exposure-outcome relationships⁴⁹.

400 A further limitation of the ability to extrapolate our results is the lack of representation in individuals of
401 diverse ancestries. The literature has demonstrated attenuation in PRS analyses where training and
402 target samples are drawn from different ancestral populations⁵⁰, highlighting the need to perform GWAS
403 in diverse ancestries. This limitation may have broader implications than would otherwise be the case
404 for some conditions, such as SLE, which disproportionately affect individuals of African and Asian
405 ancestry.

406 Although every effort has been made to address the potential for misclassification bias through the
407 criteria for multiple-item endorsements in strictly-defined cases, the approach remains imperfect. For
408 example, limited sample size led to us combine Thyroiditis and Grave’s disease, which have opposing
409 thyroid function, under the broader classification of autoimmune thyroid disease.

410 Despite the scale of the UKB, power calculations showed that for some rare autoimmune diseases, larger
411 samples would be required to reject the presence of a weak genetic correlation with depression. We
412 also observed low SNP-based heritability using published summary statistics for multiple sclerosis, which
413 reduced power to detect pleiotropic effects. The Bonferroni correction applied to cross-trait PRS
414 analyses was conservative since the eight PRS p-value thresholds included in each test of association are
415 correlated, although it is difficult to determine the appropriate correction and we chose to be strict
416 rather than liberal.

417 Conclusions

418 We identified cases and controls for depression and fourteen autoimmune diseases in the UKB, using
419 both strict and liberal phenotyping. PRS analyses indicated that strict phenotyping improved the validity
420 of cases, demonstrating that multiple UKB variables can be leveraged to increase specificity. Consistent
421 with the literature, we found that depression was enriched in autoimmune cases, and vice-versa. Despite
422 having power to detect subtle pleiotropic effects, we found little evidence that shared genetic factors
423 have a meaningful influence on the observed co-occurrence of depression and autoimmune diseases in
424 the UK Biobank. The limited shared genetic component will make only a modest contribution to the bi-
425 directional disease risks, and shared environmental factors, including health-related characteristics and
426 stressful life events, may be important. Future studies leveraging phenotypic, genetic, diagnostic,
427 treatment and environmental risk factors may be necessary to unpick the mechanisms contributing to
428 shared risks for autoimmune diseases and depression. In particular, future research should consider the

429 psychological impacts of autoimmune disease while remaining cognizant of the need to consider and
430 treat the two diseases in parallel.

431 Funding

432 This work was supported by the UK Medical Research Council (PhD studentship to KPG; grant
433 MR/N015746/1). This paper represents independent research part-funded by the National Institute for
434 Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation
435 Trust and King's College London. The views expressed are those of the authors and not necessarily those
436 of the NHS, the NIHR or the Department of Health and Social Care.

437 Acknowledgements

438 We thank participants and scientists involved in making the UK Biobank resource available
439 (<http://www.ukbiobank.ac.uk/>). The UKB received ethical approval from the North West - Haydock
440 Research Ethics Committee (reference 16/NW/0274). This study was conducted under application
441 number 18177. We thank the research participants and employees of 23andMe for making this work
442 possible. The MDD GWAS summary statistics results from 23andMe were available through a Data
443 Transfer Agreement between 23andMe, Inc., and King's College, London. Only summary statistics were
444 shared with no individual level data. 23andMe participants provided informed consent and participated
445 in the research online. The 23andMe protocol was approved by an external Association for the
446 Accreditation of Human Research Protection Programs accredited Institutional Review Board, Ethical
447 and Independent Review Services. Participants were included in the analysis on the basis of consent
448 status as checked at the time data analyses were initiated. Statistical analyses were carried out on the
449 King's Health Partners High Performance Compute Cluster funded with capital equipment grants from
450 the GSTT Charity (TR130505) and Maudsley Charity (980). We thank Nick Dand, Satveer Mahil and

451 Catherine Smith of King's College London for their contribution in identifying medications used in the
452 treatment of Psoriasis in the UKB.

453 [Data Code and Availability](#)

454 Available from UK Biobank subject to standard procedures (www.ukbiobank.ac.uk). The full GWAS
455 summary statistics for the 23andMe discovery data set will be made available through 23andMe to
456 qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe
457 participants. Please visit <https://research.23andme.com/collaborate/#publication> for more information
458 and to apply to access the data.

459 The code used during this study are available at GitHub:
460 https://github.com/kglanville/pleiotropy_autoimmune_depression_ukb.

461 [Author contributions](#)

462 Conceptualisation and study design: KPG, CML, JG, PFO. Analysis and manuscript: KPG. Analytical
463 consultation and interpretation: CML, JG, PFO, JRIC. UKB data curation and management: JRIC, KPG.
464 Genetic data preparation: JRIC, KPG. Project supervisors: CML, JG, PFO. All authors critically edited the
465 paper.

466 [Declaration of Interest](#)

467 CML is a member of the SAB for Myriad Neuroscience. The remaining authors declare no competing
468 interests.

469 References

- 470 1. Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, et al.
471 Autoimmune Diseases and Severe Infections as Risk Factors for Mood Disorders A
472 Nationwide Study. *JAMA Psychiatry*. American Medical Association; 2013
473 Aug;70(8):812–20.
- 474 2. Anderson RJ, Freedberg KA, Clouse RE, Lustman PJ. The Prevalence of Comorbid
475 Depression in Adults With Diabetes. *Diabetes Care*. 2001 Jun;24(6):1069–78.
- 476 3. Patten SB, Beck CA, Williams JVA, Barbui C, Metz LM. Major depression in multiple
477 sclerosis: A population-based perspective. *Neurology*. 61st ed. 2003 Dec;:1524–7.
- 478 4. Kurina L, Goldacre M, Yeates D, Gill L. Depression and anxiety in people with
479 inflammatory bowel disease. *Journal of Epidemiology and Community Health*. BMJ
480 Publishing Group; 2001 Oct 1;55(10):716–20.
- 481 5. Andersson NW, Gustafsson LN, Okkels N, Taha F, Cole SW, Munk-Jorgensen P, et al.
482 Depression and the risk of autoimmune disease: a nationally representative, prospective
483 longitudinal study. *Psychol Med*. Cambridge University Press; 2015 Dec;45(16):3559–
484 69.
- 485 6. Liu X, Nudel R, Thompson WK, Appadurai V, Schork AJ, Buil A, et al. Genetic factors
486 underlying the bidirectional relationship between autoimmune and mental disorders –
487 findings from a Danish population-based study. *Brain, Behavior, and Immunity*.
488 Academic Press; 2020 Jun 11.
- 489 7. Glanville KP, Coleman JRI, Hanscombe KB, Euesden J, Choi SW, Purves KL, et al.
490 Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly
491 Associated With Depression. *Biological Psychiatry*. Elsevier; 2020 Mar 1;87(5):419–30.
- 492 8. Nudel R, Benros ME, Krebs MD, Allesøe RL, Lemvig CK, Bybjerg-Grauholm J, et al.
493 Immunity and mental illness: findings from a Danish population-based immunogenetic
494 study of seven psychiatric and neurodevelopmental disorders. *European Journal of*
495 *Human Genetics*. Nature Publishing Group; 2019 Apr 11;8(1):1.
- 496 9. Hu X, Daly M. What have we learned from six years of GWAS in autoimmune diseases,
497 and what is next? *Current Opinion in Immunology*. Elsevier Current Trends; 2012 Oct
498 1;24(5):571–5.
- 499 10. Euesden J, Danese A, Lewis CM, Maughan B. A bidirectional relationship between
500 depression and the autoimmune disorders - New perspectives from the National Child
501 Development Study. *PLOS ONE*. Public Library of Science; 2017 Mar;12(3):1–14.

- 502 11. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al.
503 Genome-wide association analyses identify 44 risk variants and refine the genetic
504 architecture of major depression. *Nature Genetics*. Nature Publishing Group; 2018
505 May;50:668–81.
- 506 12. Pouget JG, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Han
507 B, Wu Y, Mignot E, Ollila HM, et al. Cross-disorder analysis of schizophrenia and 19
508 immune-mediated diseases identifies shared genetic risk. *Human Molecular Genetics*.
509 2019 Jun 18.
- 510 13. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
511 resource with deep phenotyping and genomic data. *Nature*. Nature Publishing Group;
512 2018 Oct 1;562(7726):203–9.
- 513 14. World Health Organization. *International Classification of Diseases (10th Edition)*.
514 Geneva: World Health Organisation; 1992.
- 515 15. Davis KAS, Coleman JRI, Adams M, Allen N, Breen G, Cullen B, et al. Mental health in
516 UK Biobank – development, implementation and results from an online questionnaire
517 completed by 157 366 participants: a reanalysis. *BJPsych Open*. Cambridge University
518 Press; 2020 Mar 1;6(2):e18.
- 519 16. Glanville KP, Coleman JRI, Howard DM, Pain O, Hanscombe KB, Jermy B, et al.
520 Multiple measures of depression to enhance validity of major depressive disorder in the
521 UK Biobank. *BJPsych Open*. Cambridge University Press; 2021 Mar 1;7(2):82.
- 522 17. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, et al. Prevalence and
523 Characteristics of Probable Major Depression and Bipolar Disorder within UK Biobank:
524 Cross-Sectional Study of 172,751 Participants. Potash JB, editor. *PLOS ONE*. 2013 Nov
525 25;8(11):e75362.
- 526 18. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
527 PLINK: rising to the challenge of larger and richer datasets. *GigaScience* [Internet]. 2015
528 Feb 25;4(1):559. Available from: www.cog-genomics.org/plink/1.9/
- 529 19. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust
530 relationship inference in genome-wide association studies. *Bioinformatics*. 2010 Nov
531 15;26(22):2867–73.
- 532 20. Choi SW. `choishingwan/GreedyRelated`: Function update. 2020 Mar 4.
- 533 21. Abraham G, Qiu Y, Inouye M. FlashPCA2: principal component analysis of Biobank-
534 scale genotype datasets. *Bioinformatics*. 2017 Sep 1;33(17):2776–8.

- 535 22. R Development Core Team. R: A language and environment for statistical computing
536 [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2008. Available from:
537 <http://www.R-project.org>
- 538 23. Dubois PCA, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, et al. Multiple
539 common variants for celiac disease influencing immune gene expression. *Nature*
540 *Genetics*. Nature Publishing Group; 2010 Apr 1;42(4):295–302.
- 541 24. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association
542 analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight
543 shared genetic risk across populations. *Nature Genetics*. Nature Publishing Group; 2015
544 Sep 1;47(9):979–86.
- 545 25. The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case
546 Control Consortium 2. Genetic risk and a primary role for cell-mediated immune
547 mechanisms in multiple sclerosis. *Nature*. Nature Publishing Group; 2011 Aug
548 1;476(7359):214–9.
- 549 26. Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, et al. A Genome-
550 Wide Association Study of Myasthenia Gravis. *JAMA neurology*. *JAMA Neurol*; 2015 Apr
551 1;72(4):396–404.
- 552 27. Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, et al. Large scale
553 meta-analysis characterizes genetic architecture for common psoriasis associated
554 variants. *Nature Communications*. Nature Publishing Group; 2017 May 24;8(1):1–8.
- 555 28. Aterido A, Cañete JD, Tornero J, Ferrándiz C, Pinto JA, Gratacós J, et al. Genetic
556 variation at the glycosaminoglycan metabolism pathway contributes to the risk of
557 psoriatic arthritis but not psoriasis. *Annals of the Rheumatic Diseases*. BMJ Publishing
558 Group Ltd; 2019 Mar 1;78(3):355–64.
- 559 29. Okada Y, Di Wu, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis
560 contributes to biology and drug discovery. *Nature*. Nature Publishing Group; 2014 Feb
561 1;506(7488):376–81.
- 562 30. Bentham J, Morris DL, Graham DSC, Pinder CL, Tomblinson P, Behrens TW, et al.
563 Genetic association analyses implicate aberrant regulation of innate and adaptive
564 immunity genes in the pathogenesis of systemic lupus erythematosus. *Nature Genetics*.
565 Nature Publishing Group; 2015 Dec 1;47(12):1457–64.
- 566 31. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data.
567 - PubMed - NCBI. *GigaScience*. 2019 Jul 15;8(7):2091.
- 568 32. Andres E, Serraj K. Optimal management of pernicious anemia. *Journal of blood*
569 *medicine*. *J Blood Med*; 2012;3:97–103.

- 570 33. Simmonds MJ, Gough SCL. Unravelling the genetic complexity of autoimmune thyroid
571 disease: HLA, CTLA-4 and beyond. *Clinical and Experimental Immunology*. Wiley-
572 Blackwell; 2004 Apr 1;136(1):1–10.
- 573 34. Bradfield JP, Qu H-Q, Wang K, Zhang H, Sleiman PM, Kim CE, et al. A Genome-Wide
574 Meta-Analysis of Six Type 1 Diabetes Cohorts Identifies Multiple Associated Loci.
575 McCarthy MI, editor. *PLoS Genet*. Public Library of Science; 2011 Sep
576 29;7(9):e1002293.
- 577 35. Spillane J, Higham E, Kullmann DM. Myasthenia gravis. *BMJ*. British Medical Journal
578 Publishing Group; 2012 Dec 21;345(dec21 3):e8497–7.
- 579 36. Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, et al. Large scale
580 meta-analysis characterizes genetic architecture for common psoriasis associated
581 variants. - PubMed - NCBI. *Nature Communications*. 2017 May 24;8:15382.
- 582 37. International Genetics of Ankylosing Spondylitis Consortium (IGAS). Identification of
583 multiple risk variants for ankylosing spondylitis through high-density genotyping of
584 immune-related loci. *Nature Genetics*. Nature Publishing Group; 2013 Jul 1;45(7):730–8.
- 585 38. Partington RJ, Muller S, Helliwell T, Mallen CD, Sultan AA. Incidence, prevalence and
586 treatment burden of polymyalgia rheumatica in the UK over two decades: a population-
587 based study. *Annals of the Rheumatic Diseases*. BMJ Publishing Group Ltd; 2018 Dec
588 1;77(12):1750–6.
- 589 39. Humphreys JH, Verstappen SMM, Hyrich KL, Chipping JR, Marshall T, Symmons DPM.
590 The incidence of rheumatoid arthritis in the UK: comparisons using the 2010
591 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from
592 the Norfolk Arthritis Register. *Annals of the Rheumatic Diseases*. BMJ Publishing Group
593 Ltd; 2013 Aug 1;72(8):1315–20.
- 594 40. Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, et al. Variants at
595 multiple loci implicated in both innate and adaptive immune responses are associated
596 with Sjögren's syndrome. *Nature Genetics*. *Nat Genet*; 2013 Oct 6;45(11):1284–92.
- 597 41. Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and
598 prevalence of systemic lupus erythematosus in the UK, 1999–2012. *Annals of the*
599 *Rheumatic Diseases*. BMJ Publishing Group Ltd; 2016 Jan 1;75(1):136–41.
- 600 42. Luigi Palla FD. A Fast Method that Uses Polygenic Scores to Estimate the Variance
601 Explained by Genome-wide Marker Panels and the Proportion of Variants Affecting a
602 Trait. *Am J Hum Genet*. Elsevier; 2015 Aug 6;97(2):250–9.
- 603 43. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Schizophrenia Working
604 Group of the Psychiatric Genomics Consortium, et al. LD Score regression distinguishes

- 605 confounding from polygenicity in genome-wide association studies. *Nature Genetics*.
606 2015 Mar;47(3):291–5.
- 607 44. Gold SM, Köhler-Forsberg O, Moss-Morris R, Mehnert A, Miranda JJ, Bullinger M, et al.
608 Comorbid depression in medical diseases. *Nat Rev Dis Primers*. Nature Publishing
609 Group; 2020 Aug 20;6(1):1–22.
- 610 45. ME L, L T, J B, J C, de Boer P, Mondelli V, et al. Peripheral Blood Cell-Stratified
611 Subgroups of Inflamed Depression. *Biological Psychiatry*. *Biol Psychiatry*; 2020 Jul
612 15;88(2):185–96.
- 613 46. Dube SR, Fairweather D, Pearson WS, Felitti VJ, Anda RF, Croft JB. Cumulative
614 Childhood Stress and Autoimmune Diseases in Adults. *Psychosomatic Medicine*. 2009
615 Feb;71(2):243–50.
- 616 47. Hughes K, Bellis MA, Hardcastle KA, Sethi D, Butchart A, Mikton C, et al. The effect of
617 multiple adverse childhood experiences on health: a systematic review and meta-
618 analysis. *The Lancet Public Health*. Elsevier; 2017 Aug 1;2(8):e356–66.
- 619 48. A F, T J L, C S, N D, L A, T S, et al. Comparison of Sociodemographic and Health-
620 Related Characteristics of UK Biobank Participants With Those of the General
621 Population. *American Journal of Epidemiology*. *Am J Epidemiol*; 2017 Nov
622 1;186(9):1026–34.
- 623 49. Batty GD, Gale C, Kivimaki M, Deary I, Bell S. Generalisability of Results from UK
624 Biobank: Comparison With a Pooling of 18 Cohort Studies. *medRxiv*. Cold Spring Harbor
625 Laboratory Press; 2019 Aug 13;:19004705.
- 626 50. Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, et al. Analysis of
627 polygenic risk score usage and performance in diverse human populations. *Nature*
628 Communications. Nature Publishing Group; 2019 Jul 25;10(1):1–9.
- 629